Skip to main content
placeholder image

A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Gu, S., de Souza, P. L., Shi, Y., Han, W., Luo, S., Chen, J., . . . Chen, X. (2022). A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 2641. doi:10.1200/jco.2022.40.16_suppl.2641

Web Of Science Accession Number


Start Page


  • 2641

End Page


  • 2641

Volume


  • 40

Issue


  • 16_suppl

Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Gu, S., de Souza, P. L., Shi, Y., Han, W., Luo, S., Chen, J., . . . Chen, X. (2022). A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), 2641. doi:10.1200/jco.2022.40.16_suppl.2641

Web Of Science Accession Number


Start Page


  • 2641

End Page


  • 2641

Volume


  • 40

Issue


  • 16_suppl